Female sex, n (%) | 126 (36) |
Age [median (IQR)] years | 50 (43 – 58) |
Ethnicity Caucasian, n (%) | 346 (99) |
HCV genotype 1/2/3 (%) | 240/25/83 (69/7/24) |
ALT [median (IQR)] U/l | 49 (28 – 86) |
Hb [median (IQR)] g/dl | 15.1 (14.2 – 16) |
Creatinine [median (IQR)] mg/dl | 0.8 (0.7 – 0.9) |
EPO# [median (IQR)] mIU/ml* | 7.8 (6 – 10.5) |
Hepatitis activity mild, n (%) | 170 (68) |
Fibrosis absent or mild, n (%) | 201 (81) |
Severe Fibrosis or Cirrhosis1, n (%) | 631 (18) |
Steatosis absent or mild, n (%) | 224 (90) |
Initial daily RBV dose2, n (%) | |
  800 mg | 37 (10) |
  1.000 mg | 125 (36) |
  1.200 mg | 110 (32) |
  1.400 mg | 76 (21) |
PEG-IFN-α treatment, n (%) | |
  PEG-IFN-α2a | 238 (68) |
  PEG-IFN-α2b 1.0 μg/kg | 30 (9) |
  PEG-IFN-α2b 1.5 μg/kg | 80 (23) |
SVR by genotype 1/2/3, n (%) | 101/20/68 (42/80/82) |
EPO rs1617640 TT/TG/GG, n (%) | 113/168/67 (33/48/19) |
ITPA rs1127354 CC/CA/AA, n (%) | 280/66/2 (80/19/1) |